Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Merck
Covington
Medtronic
Daiichi Sankyo
US Army
UBS
Julphar
Baxter

Generated: May 27, 2018

DrugPatentWatch Database Preview

DESONATE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Desonate patents expire, and when can generic versions of Desonate launch?

Desonate is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-four patent family members in twenty-two countries.

The generic ingredient in DESONATE is desonide. There are thirty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the desonide profile page.
Drug patent expirations by year for DESONATE
Pharmacology for DESONATE
Medical Subject Heading (MeSH) Categories for DESONATE
Synonyms for DESONATE
(11ss,16alpha)-11,21-Dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione
(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0;{2,9}.0;{4,8}.0;{13,18}]icosa-14,17-dien-16-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone
11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione
16-alpha-Hydroxyprednisole-16,17-acetonide
16?,17-[1-Methylethylidenebis(oxy)]-11?,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha-hydroxyprednisole-16,17-acetonide
16alpha-hydroxyprednisolone-16alpha,17-acetonide
16alpha,17-[1-Methylethylidenebis(oxy)]-11beta,21-dihydroxypregna-1,4-diene-3,20-dione (Desonide)
16alpha,17alpha-isopropylidenedioxyprednisolone
638-94-8
638D948
AB01274712_02
AB01274712-01
AB2000229
Apolar
AS-13892
budesonide acetonide
C-22009
CAS-638-94-8
CC-26356
CCG-221279
CHEBI:204734
CHEMBL1201109
CS-2228
D 2083
D-2083
D02JNM
D03696
D2083
DB01260
desfluorotriamcinolone acetonide
Desilux
Desonida
Desonida [INN-Spanish]
DESONIDE
Desonide (USAN/INN)
Desonide [USAN:INN:BAN]
Desonidum
Desonidum [INN-Latin]
DesOwen
Desowen (TN)
DSSTox_CID_26756
DSSTox_GSID_46756
DSSTox_RID_81880
DTXSID7046756
EINECS 211-351-6
Flusemidon
GTPL7066
Hamiltoderm
HY-B0248
J280872D1O
K016
Locapred
Locapred, Topifug, Tridesilon, Desonide
Locapred;Topifug;Tridesilon
MolPort-003-987-087
NCGC00167983-01
NCGC00274065-01
Prednacinolone
Prednisolone-16,17-acetonide, 16-alpha-hydroxy-
Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-
Prenacid
Q-101382
Reticus
s1701
SC-17104
SCHEMBL3631
Sterax
Steroderm
TL8004516
Topifug
Tox21_112603
Tox21_112603_1
Tridesilon
Tridesonit
UNII-J280872D1O
Verdeso
Verdeso (TN)
Verdeso Foam (TN)
WBGKWQHBNHJJPZ-LECWWXJVSA-N
ZINC4212851
Zotinar

US Patents and Regulatory Information for DESONATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare DESONATE desonide GEL;TOPICAL 021844-001 Oct 20, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for DESONATE
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Gel 0.05% ➤ Subscribe 2010-12-01

Non-Orange Book US Patents for DESONATE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,517,847 Topical gel delivery system ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for DESONATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013025 Lithuania ➤ Try a Free Trial PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1304992/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
2013025,C1304992 Lithuania ➤ Try a Free Trial PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
00617 Netherlands ➤ Try a Free Trial PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Deloitte
Accenture
US Department of Justice
Federal Trade Commission
Moodys
Teva
Citi
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.